{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"184"},{"groupId":"BG006","value":"156"},{"groupId":"BG007","value":"168"},{"groupId":"BG008","value":"60"},{"groupId":"BG009","value":"90"},{"groupId":"BG010","value":"21"},{"groupId":"BG011","value":"18"},{"groupId":"BG012","value":"50"},{"groupId":"BG013","value":"51"},{"groupId":"BG014","value":"53"},{"groupId":"BG015","value":"44"},{"groupId":"BG016","value":"125"},{"groupId":"BG017","value":"62"},{"groupId":"BG018","value":"20"},{"groupId":"BG019","value":"103"},{"groupId":"BG020","value":"205"},{"groupId":"BG021","value":"132"},{"groupId":"BG022","value":"153"},{"groupId":"BG023","value":"1756"}],"units":"Participants"}],"groups":[{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG000","title":"Dose Escalation Cohort: Avelumab 1.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.","id":"BG001","title":"Dose Escalation Cohort: Avelumab 3.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG002","title":"Dose Escalation Cohort: Avelumab 10.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG003","title":"Dose Escalation Cohort: Avelumab 20.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once weekly for the first 12 weeks and once every 2 weeks starting Week 13 in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG004","title":"Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly"},{"description":"Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG005","title":"Primary Expansion Cohort: NSCLC, Post-platinum Doublet"},{"description":"Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG006","title":"Primary Expansion Cohort: NSCLC, First Line"},{"description":"Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG007","title":"Primary Expansion Cohort: Metastatic Breast Cancer"},{"description":"Participants with gastric and gastroesophageal cancer who progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG008","title":"Primary Expansion Cohort: GC/GEJC Progressed"},{"description":"Participants with gastric and gastroesophageal cancer who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG009","title":"Primary Expansion Cohort: GC/GEJC Non Progressed"},{"description":"Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG010","title":"Secondary Expansion Cohort: Colorectal Cancer"},{"description":"Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG011","title":"Secondary Expansion Cohort: Castrate-resistant Prostate Cancer"},{"description":"Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG012","title":"Secondary Expansion Cohort: Adrenocortical Carcinoma"},{"description":"Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG013","title":"Secondary Expansion Cohort: Melanoma"},{"description":"Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG014","title":"Secondary Expansion Cohort: Mesothelioma"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG015","title":"Secondary Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG016","title":"Secondary Expansion Cohort: Ovarian Cancer"},{"description":"Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG017","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)"},{"description":"Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG018","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG019","title":"Efficacy Expansion Cohort: Ovarian Cancer"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG020","title":"Efficacy Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG021","title":"Efficacy Expansion Cohort: GC/GEJC, Third Line"},{"description":"Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"BG022","title":"Efficacy Expansion Cohort: HNSCC"},{"description":"Total of all reporting groups","id":"BG023","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"90"},{"groupId":"BG006","value":"51"},{"groupId":"BG007","value":"140"},{"groupId":"BG008","value":"38"},{"groupId":"BG009","value":"61"},{"groupId":"BG010","value":"19"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"46"},{"groupId":"BG013","value":"28"},{"groupId":"BG014","value":"20"},{"groupId":"BG015","value":"11"},{"groupId":"BG016","value":"74"},{"groupId":"BG017","value":"37"},{"groupId":"BG018","value":"7"},{"groupId":"BG019","value":"52"},{"groupId":"BG020","value":"66"},{"groupId":"BG021","value":"91"},{"groupId":"BG022","value":"97"},{"groupId":"BG023","value":"980"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"94"},{"groupId":"BG006","value":"105"},{"groupId":"BG007","value":"28"},{"groupId":"BG008","value":"22"},{"groupId":"BG009","value":"29"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"4"},{"groupId":"BG013","value":"23"},{"groupId":"BG014","value":"33"},{"groupId":"BG015","value":"33"},{"groupId":"BG016","value":"51"},{"groupId":"BG017","value":"25"},{"groupId":"BG018","value":"13"},{"groupId":"BG019","value":"51"},{"groupId":"BG020","value":"139"},{"groupId":"BG021","value":"41"},{"groupId":"BG022","value":"56"},{"groupId":"BG023","value":"776"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"84"},{"groupId":"BG006","value":"73"},{"groupId":"BG007","value":"167"},{"groupId":"BG008","value":"14"},{"groupId":"BG009","value":"22"},{"groupId":"BG010","value":"7"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"26"},{"groupId":"BG013","value":"17"},{"groupId":"BG014","value":"21"},{"groupId":"BG015","value":"14"},{"groupId":"BG016","value":"125"},{"groupId":"BG017","value":"19"},{"groupId":"BG018","value":"5"},{"groupId":"BG019","value":"103"},{"groupId":"BG020","value":"57"},{"groupId":"BG021","value":"47"},{"groupId":"BG022","value":"28"},{"groupId":"BG023","value":"861"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"100"},{"groupId":"BG006","value":"83"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"46"},{"groupId":"BG009","value":"68"},{"groupId":"BG010","value":"14"},{"groupId":"BG011","value":"18"},{"groupId":"BG012","value":"24"},{"groupId":"BG013","value":"34"},{"groupId":"BG014","value":"32"},{"groupId":"BG015","value":"30"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"43"},{"groupId":"BG018","value":"15"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"148"},{"groupId":"BG021","value":"85"},{"groupId":"BG022","value":"125"},{"groupId":"BG023","value":"895"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"5"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"13"},{"groupId":"BG009","value":"35"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"6"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"7"},{"groupId":"BG020","value":"15"},{"groupId":"BG021","value":"42"},{"groupId":"BG022","value":"19"},{"groupId":"BG023","value":"163"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"4"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"16"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"3"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"1"},{"groupId":"BG019","value":"4"},{"groupId":"BG020","value":"9"},{"groupId":"BG021","value":"6"},{"groupId":"BG022","value":"4"},{"groupId":"BG023","value":"91"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"159"},{"groupId":"BG006","value":"124"},{"groupId":"BG007","value":"141"},{"groupId":"BG008","value":"36"},{"groupId":"BG009","value":"44"},{"groupId":"BG010","value":"17"},{"groupId":"BG011","value":"12"},{"groupId":"BG012","value":"32"},{"groupId":"BG013","value":"35"},{"groupId":"BG014","value":"43"},{"groupId":"BG015","value":"35"},{"groupId":"BG016","value":"114"},{"groupId":"BG017","value":"35"},{"groupId":"BG018","value":"19"},{"groupId":"BG019","value":"91"},{"groupId":"BG020","value":"155"},{"groupId":"BG021","value":"70"},{"groupId":"BG022","value":"96"},{"groupId":"BG023","value":"1310"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"7"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"14"},{"groupId":"BG013","value":"12"},{"groupId":"BG014","value":"10"},{"groupId":"BG015","value":"4"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"20"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"25"},{"groupId":"BG021","value":"12"},{"groupId":"BG022","value":"34"},{"groupId":"BG023","value":"183"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}